Lillian van de Verg - JoVE Visualize

Showing results (1-10 of 5) with videos related to

Pageof 1

Sort By:

Expert Review of Vaccines|May 4, 2012

Vaccines for enteric diseases: a meeting summaryDuncan Steele, Mark Riddle, Lillian van de Verg, et al.

Infection and Immunity|June 18, 2002

Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane proteinApurba K Bhattacharjee, Lillian Van de Verg, Mina J Izadjoo, et al.

Clinical and Vaccine Immunology : CVI|February 12, 2016

Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult SubjectsSubhra Chakraborty, Clayton Harro, Barbara DeNearing, et al.

Clinical and Vaccine Immunology : CVI|September 20, 2013

Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coliSamer S El-Kamary, Mitchell B Cohen, A Louis Bourgeois, et al.

Journal of Immunology (Baltimore, Md. : 1950)|January 24, 2014

Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypesShannon J Heine, Jovita Diaz-McNair, Abhay U Andar, et al.

Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:

Pageof 1

Expert Review of Vaccines|May 4, 2012

Vaccines for enteric diseases: a meeting summaryDuncan Steele, Mark Riddle, Lillian van de Verg, et al.

Infection and Immunity|June 18, 2002

Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane proteinApurba K Bhattacharjee, Lillian Van de Verg, Mina J Izadjoo, et al.

Clinical and Vaccine Immunology : CVI|February 12, 2016

Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult SubjectsSubhra Chakraborty, Clayton Harro, Barbara DeNearing, et al.

Clinical and Vaccine Immunology : CVI|September 20, 2013

Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coliSamer S El-Kamary, Mitchell B Cohen, A Louis Bourgeois, et al.

Journal of Immunology (Baltimore, Md. : 1950)|January 24, 2014

Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypesShannon J Heine, Jovita Diaz-McNair, Abhay U Andar, et al.

Pageof 1